

available at www.sciencedirect.comjournal homepage: www.ejconline.com

Erratum

Erratum to “To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound” [European Journal of Cancer, 42 (2006) 2472–2479]

Michele Lamuraglia^{a,c}, Bernard Escudier^b, Linda Chami^a, Brian Schwartz^d,
Jérôme Leclère^a, Alain Roche^a, Nathalie Lassau^{a,*}

^aDepartment of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France

^bDepartment of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France

^cSection of Internal Medicine, Department of Internal Medicine and Public Medicine, University of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy

^dBayer Pharmaceuticals Corporation, West Haven, CT 06516, USA

The Publisher regrets the incorrect classification of the above mentioned article as a review paper. This paper is part of the Clinical Oncology Section of the journal.

DOI of original article: [10.1016/j.ejca.2006.04.023](https://doi.org/10.1016/j.ejca.2006.04.023)

* Corresponding author: Tel.: +33 1 42 11 60 14; fax: +33 1 42 11 60 29.

E-mail address: lassau@igr.fr (N. Lassau).

0959-8049/\$ - see front matter © 2006 Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejca.2006.04.034